← Eichor
Study identifier: NCT05665699 Synced from ClinicalTrials.gov · July 31, 2026
● Completed

Phase II Study to Evaluate Efficacy and Safety of D-0120 in Combination With Allopurinol in Subjects With Gout

Condition: Gout  ·  Sponsor: InventisBio Co., Ltd

PhasePhase 2
Planned participants80
Who can joinAll sexes, 18 Years to 75 Years
Healthy volunteersNo

About this study

D-0120 is being tested in combination with Allopurinol in adult subjects with Gout.

This description comes directly from the study's public registry record.

Talk to the study team

Contact details are listed per location below or on the registry record.

Always discuss trial participation with your own doctor first.

Locations (19)

Study CenterBirmingham, Alabama, United States
Site CenterPlantation, Florida, United States
Study CenterEvergreen Park, Illinois, United States
Study CenterBrownsburg, Indiana, United States
Site CenterLouisville, Kentucky, United States
Study CenterHickory, North Carolina, United States
Study CenterRocky Mount, North Carolina, United States
Study CenterSalisbury, North Carolina, United States
Study CenterWilmington, North Carolina, United States
Study CenterWinston-Salem, North Carolina, United States
Study CenterScottdale, Pennsylvania, United States
Study CenterBristol, Tennessee, United States

+ 7 more locations — full list on the registry record.

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT05665699